Relmada Therapeutics, Inc. RLMD Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost

Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost at other companies

Relmada Therapeutics, Inc.RLMD

-2%—

Lincoln Educational Services CorporationLINC

-2%—

Rumble, Inc.RUM

-2.9%-3.7pp

Monro, Inc.MNRO

-8.1%-9.1pp

Century CommunitiesCCS

1.6%+0.1pp

Artesian ResourcesARTNA

0%—

Operating income-$19.5M-6.8%

Net income-$19.1M-8.5%

EPS (diluted)-$0.22+62.1%

Cash & equivalents$9.8M+750%

Total debt$104.1M-40.4%

Total equity$218.7M+875%

Total assets$235.4M+750%

Operating cash flow-$15.1M+16.6%

Market cap$677.17M+2,907%

Return on equity-48.8%-20.0pp

Debt / equity0.9×0.0×

Current ratio18.3×+13.0×

Reported directly by Relmada Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost.

The official record: Relmada Therapeutics, Inc.’s 10-K, filed March 19, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Relmada Therapeutics, Inc.'s effective income tax rate reconciliation nondeductible expense share based compensation cost?: Relmada Therapeutics, Inc. (RLMD) reported effective income tax rate reconciliation nondeductible expense share based compensation cost of -2% in Q4 2025.
What does effective income tax rate reconciliation nondeductible expense share based compensation cost mean?: This metric quantifies the impact of non-deductible share-based compensation expenses on the company's effective tax rate. It helps investors understand how equity compensation policies influence the overall tax burden relative to statutory rates.